en · de · es · fr · pt
peptide-index.peptides7501.com › News › Background And Research Status — Evidence Review

Background And Research Status — Evidence Review

By Editorial Desk · published 2025-10-16 · last reviewed 2025-10-31 · News

The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2025-10-31 and is reviewed periodically as new material appears.

Background and Research Status

REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.

Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.

SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.

Detection, Regulation, and Misconceptions

Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.

Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.

Sr9009 at a glance

PropertyValueNotes
Common nameSR9009Also referred to as Stenabolic in non-scientific contexts.
Chemical classSynthetic small moleculeNot a steroid or peptide hormone.
Receptor targetREV-ERBα and REV-ERBβNuclear receptor agonist in preclinical studies.
Development statusInvestigationalNo approved human therapeutic indication.
Regulatory attentionProhibited in sportListed by anti-doping authorities.

Mechanism and Preclinical Findings

The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.

SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.

Related pages on this site

Further detail

== History == The term gynaecomastia was coined by Galen. He also recognised glandular enlargement of the male breast; however, this wasn't a condition of gynaecomastia according to him. A surgical procedure for treatment of gynaecomastia was described by Albucasis in his second book of Kitab al-Tasrif.

== Double meaning == The use of the word "faggot" has caused misunderstanding due to its meaning as a pejorative term for a homosexual man. In 2004, a radio commercial for the UK supermarket chain Somerfield, in which a man rejects his wife's suggested dinner saying "I've got nothing against faggots, I just don't fancy them" was found to have been innuendo which breached the Advertising and Sponsorship Code and was banned by the industry regulator Ofcom. Additionally, the term caused multiple instances of the scunthorpe problem, where profanity filters erroneously blocked the term regardless of its use in context. In November 2013, it was reported that British Facebook users had been blocked temporarily for using the word, in its culinary sense, on the website. Facebook said that the word had been misinterpreted. In September 2019, a Google Ads advertisement for a British cafe was removed for featuring the term.

=== Internal genetic structure === The internal genetic structure of the Han Chinese is consistent with the vast geographical expanse of China. The reference population for the Han Chinese used in Geno 2.0 Next Generation is 81% Eastern Asia, 2% Finland and Northern Siberia, 8% Central Asia, and 7% Southeast Asia & Oceania. The recorded history of large migratory waves over the past several millennia have also engendered the emergence of diverse Han subgroups, who display slight but discernible physical and physiological differences. Although genetically similar, Han Chinese subgroups exhibit a north–south stratification in their genetics, with centrally placed populations acting as conduits for outlying ones. Despite no clear genetic divide between the north and south due to the Han Chinese being a clinal population, many studies simply categorize the Han Chinese into two subgroups out of convenience: Northern and Southern Han Chinese. Several genetic studies show that both Northern and Southern Han Chinese share ancestry with Neolithic Chinese populations from the Central Plains. Northern Han Chinese and Southern Han Chinese can be modeled as having Neolithic Yellow River and Kra-Dai-speaking ancestries, although Kra-Dai ancestry is more common in Southern Han. Despite shared Neolithic Yellow River ancestry, Han sub-groups slightly differ in their ancestral components, reflective of their vast demographic history. Specifically, they tend to share some maternal ancestry with geographically close minority groups.

The isotopes neptunium-235, -236, and -237 are predicted to be fissile; although only neptunium-237's fissionability has been experimentally shown. Its critical mass is about 60 kg, only about 10 kg more than that of the commonly used uranium-235. Calculated values of the critical masses of neptunium-235, -236, and -237 respectively are 66.2 kg, 6.79 kg, and 63.6 kg: the neptunium-236 value is even lower than that of plutonium-239 and 236Np also has a low neutron cross section. However, a neptunium atomic bomb has never been built because uranium and plutonium have lower critical masses than 235Np and 237Np, and 236Np is difficult to purify as it is not found in quantity in spent nuclear fuel and is nearly impossible to separate in any significant quantities from 237Np.

== Efficacy == A Cochrane systematic review assessed the effect of alpha-glucosidase inhibitors (acarbose and voglibose) in people with impaired glucose tolerance, impaired fasting blood glucose, elevated glycated hemoglobin A1c (HbA1c). Trials of people diagnosed with “metabolic syndrome” or such with an intervention duration of less than one year were excluded from this systematic review. The authors concluded that “[i]n people with intermediate hyperglycaemia the use of alpha‐glucosidase inhibitors [including voglibose] reduces or delays the incidence of type 2 diabetes mellitus”, but “[t]here is no firm evidence that alpha‐glucosidase inhibitors prevent cardiovascular mortality and morbidity.” The results of this review are overall rather uncertain because of “systematic errors in some of the included trials, the overall low number of trials for a particular outcome, imprecise results and missing data of one included trial [“EDIT 1997”, which investigated acarbose, not voglibose].” The authors investigated in total two studies on voglibose, one which compared it to placebo, one which compared it to diet plus exercise. While the latter one was criticized for imprecision, in the first one, the amount of patients developing diabetes mellitus type 2 was reduced by more than 50% in patients treated with voglibose (5.6%) compared to those treated with placebo (12%). However, this was classified as “low‐certainty evidence”.

Sources: en.wikipedia.org

Background from the literature

=== Bio-based coloured materials === Cellulose nanocrystals have shown the possibility to self organize into chiral nematic structures with angle-dependent iridescent colours. It is thus possible to manufacture totally bio-based pigments and glitters, films including sequins having a metallic glare and a small footprint compared to fossil-based alternatives.

Various work-related elements impact overall well-being, such as the character of the work performed, income, job security, work-life balance, and personal relationships to coworkers and superiors. Job loss and unemployment are associated with a decrease in well-being because of factors such as financial strain caused by lost wages, weakened social connections, and a reduced sense of purpose and social status. The government and political situation, another determinant, influences the happiness of the population by affecting security, equality, social services, and a general trust in society. Accordingly, governments that uphold the rule of law, provide good services, and control corruption tend to foster higher levels of well-being. Opportunities to democratically participate in political decision-making are also linked to increased well-being. Similarly, the physical environment plays a role, with factors like housing conditions, pollution, noise, and access to nature and recreational areas. The genetic makeup can significantly impact the general level of a person's well-being, with some studies suggesting that genetic influences can explain up to one third of the differences in subjective well-being. For example, the life satisfaction of identical twins, who share genes, is more alike than the life satisfaction of non-identical twins. Other relevant biological factors include neurotransmitters and hormones.

The vast majority of insulin used worldwide is biosynthetic recombinant human insulin or its analogues. Recently, another recombinant approach has been used by a pioneering group of Canadian researchers, using an easily grown safflower plant, for the production of much cheaper insulin. Recombinant insulin is produced either in yeast (usually Saccharomyces cerevisiae) or E. coli. In yeast, insulin may be engineered as a single-chain protein with a KexII endoprotease (a yeast homolog of PCI/PCII) site that separates the insulin A chain from a C-terminally truncated insulin B chain. A chemically synthesized C-terminal tail containing the missing threonine is then grafted onto insulin by reverse proteolysis using the inexpensive protease trypsin; typically the lysine on the C-terminal tail is protected with a chemical protecting group to prevent proteolysis. The ease of modular synthesis and the relative safety of modifications in that region accounts for common insulin analogs with C-terminal modifications (e.g. lispro, aspart, glulisine). The Genentech synthesis and completely chemical synthesis such as that by Bruce Merrifield are not preferred because the efficiency of recombining the two insulin chains is low, primarily due to competition with the precipitation of insulin B chain.

== Application to drugs == The hydrogen bond is relevant to drug design. According to Lipinski's rule of five the majority of orally active drugs have no more than five hydrogen bond donors and fewer than ten hydrogen bond acceptors. These interactions exist between nitrogen–hydrogen and oxygen–hydrogen centers. Many drugs do not, however, obey these "rules".

Each size exclusion column has a range of molecular weights that can be separated. The exclusion limit defines the molecular weight at the upper end of the column 'working' range and is where molecules are too large to get trapped in the stationary phase. The lower end of the range is defined by the permeation limit, which defines the molecular weight of a molecule that is small enough to penetrate all pores of the stationary phase. All molecules below this molecular mass are so small that they elute as a single band. The filtered solution that is collected at the end is known as the eluate. The void volume includes any particles too large to enter the medium, and the solvent volume is known as the column volume. Following are the materials which are commonly used for porous gel beads in size exclusion chromatography

Sources: en.wikipedia.org

Frequently asked questions

What is SR9009?

It is a synthetic compound studied as an agonist of REV-ERB nuclear receptors. It is not an approved medicine and has mainly been examined in laboratory and animal research.

Is SR9009 a steroid?

No. It is a small molecule that binds nuclear receptors involved in circadian regulation. Its classification differs from anabolic steroids or peptide hormones.

Has SR9009 been tested in humans?

Published human clinical trial data are lacking. Most safety and activity information comes from preclinical models, so effects in people remain uncertain.

Is SR9009 legal to buy?

Legality depends on the country and the intended use. In many places it is not approved as a medicine and may be sold only as a research chemical. Importation or possession can be restricted, and sports organizations prohibit it.

Network